BR112019010553A2 - método para inferir a atividade de uma via de sinalização celular pi3k em um indivíduo e programa de computador - Google Patents

método para inferir a atividade de uma via de sinalização celular pi3k em um indivíduo e programa de computador

Info

Publication number
BR112019010553A2
BR112019010553A2 BR112019010553A BR112019010553A BR112019010553A2 BR 112019010553 A2 BR112019010553 A2 BR 112019010553A2 BR 112019010553 A BR112019010553 A BR 112019010553A BR 112019010553 A BR112019010553 A BR 112019010553A BR 112019010553 A2 BR112019010553 A2 BR 112019010553A2
Authority
BR
Brazil
Prior art keywords
infer
signaling pathway
cell signaling
individual
activity
Prior art date
Application number
BR112019010553A
Other languages
English (en)
Inventor
Van De Stolpe Anja
Jan Van Ooijen Hendrik
Theodorus Lambert Akse Martijn
Velter Rick
Franciscus Johannes Verhaegh Wilhelmus
Original Assignee
Koninklijke Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Nv filed Critical Koninklijke Philips Nv
Publication of BR112019010553A2 publication Critical patent/BR112019010553A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Probability & Statistics with Applications (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

a presente invenção se refere a certos genes-alvo da família do fator de transcrição foxo, que são marcadores de um estado de estresse oxidativo e podem ser usados para inferir um estado de estresse oxidativo de um elemento do fator de transcrição foxo no corpo de um indivíduo médico. a invenção se refere adicionalmente a métodos para inferir um estado de estresse oxidativo de um elemento do fator de transcrição foxo e para inferir a atividade da via de sinalização celular foxo/pi3k com base em níveis de expressão dos genes-alvo bem como nos produtos para executar os métodos.
BR112019010553A 2016-11-25 2017-11-24 método para inferir a atividade de uma via de sinalização celular pi3k em um indivíduo e programa de computador BR112019010553A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16200697 2016-11-25
PCT/EP2017/080298 WO2018096076A1 (en) 2016-11-25 2017-11-24 Method to distinguish tumor suppressive foxo activity from oxidative stress

Publications (1)

Publication Number Publication Date
BR112019010553A2 true BR112019010553A2 (pt) 2019-09-10

Family

ID=57538997

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019010553A BR112019010553A2 (pt) 2016-11-25 2017-11-24 método para inferir a atividade de uma via de sinalização celular pi3k em um indivíduo e programa de computador

Country Status (8)

Country Link
US (1) US20190376142A1 (pt)
EP (2) EP3544993A1 (pt)
JP (1) JP7186700B2 (pt)
CN (1) CN110382521B (pt)
AU (1) AU2017364218A1 (pt)
BR (1) BR112019010553A2 (pt)
CA (1) CA3044709A1 (pt)
WO (1) WO2018096076A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3431582A1 (en) * 2017-07-18 2019-01-23 Koninklijke Philips N.V. Cell culturing materials
CN111587293A (zh) 2017-10-02 2020-08-25 皇家飞利浦有限公司 确定免疫细胞类型和免疫应答的功能状态
CN113785075A (zh) 2019-05-03 2021-12-10 皇家飞利浦有限公司 高级别浆液性卵巢癌的预后方法
EP3812474A1 (en) 2019-10-22 2021-04-28 Koninklijke Philips N.V. Methods of prognosis in high-grade serous ovarian cancer
EP3739588A1 (en) 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
CN110747197B (zh) * 2019-12-05 2023-05-26 广西国际壮医医院 一种人内源性27nt-miRNA分子在制备抗肿瘤药物中的应用
EP3882363A1 (en) 2020-03-17 2021-09-22 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
EP3978628A1 (en) 2020-10-01 2022-04-06 Koninklijke Philips N.V. Prognostic pathways for viral infections
EP4136261A1 (en) 2020-04-16 2023-02-22 InnoSIGN B.V. Prognostic pathways for viral infections
EP3940704A1 (en) 2020-07-14 2022-01-19 Koninklijke Philips N.V. Method for determining the differentiation state of a stem cell
EP3965119A1 (en) 2020-09-04 2022-03-09 Koninklijke Philips N.V. Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices
EP3974540A1 (en) 2020-09-25 2022-03-30 Koninklijke Philips N.V. Method for predicting immunotherapy resistance
EP4015651A1 (en) 2020-12-17 2022-06-22 Koninklijke Philips N.V. Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients
EP4039825A1 (en) 2021-02-09 2022-08-10 Koninklijke Philips N.V. Comparison and standardization of cell and tissue culture
WO2022189530A1 (en) 2021-03-11 2022-09-15 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
CN113284611B (zh) * 2021-05-17 2023-06-06 西安交通大学 基于个体通路活性的癌症诊断和预后预测系统、设备及存储介质
CN116144667B (zh) * 2022-12-29 2024-03-12 海南大学 卵形鲳鲹胰岛素样生长因子结合蛋白1基因、蛋白及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132479A2 (en) * 2009-05-11 2010-11-18 Cytotech Labs, Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US20130316948A1 (en) * 2011-02-08 2013-11-28 University Of Southern California Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
CA2896414C (en) 2012-12-26 2023-06-20 Koninklijke Philips N.V. Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions
US11261495B2 (en) * 2014-01-03 2022-03-01 Koninklijke Philips N.V. Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression
CN108064311B (zh) * 2014-10-24 2022-10-28 皇家飞利浦有限公司 使用多种细胞信号传导途径活性的治疗反应的医学预后和预测

Also Published As

Publication number Publication date
CN110382521B (zh) 2024-07-05
US20190376142A1 (en) 2019-12-12
JP2020503850A (ja) 2020-02-06
EP3763732A1 (en) 2021-01-13
CN110382521A (zh) 2019-10-25
AU2017364218A1 (en) 2019-07-11
WO2018096076A1 (en) 2018-05-31
CA3044709A1 (en) 2018-05-31
EP3544993A1 (en) 2019-10-02
JP7186700B2 (ja) 2022-12-09

Similar Documents

Publication Publication Date Title
BR112019010553A2 (pt) método para inferir a atividade de uma via de sinalização celular pi3k em um indivíduo e programa de computador
CO2018004564A2 (es) Genes de ataxia de friedreich modificados y vectores para terapia génica
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
CL2018000803A1 (es) Composiciones y métodos para inhibir la expresión génica de lpa.
BR112019000195A2 (pt) composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno
BR112016003868A8 (pt) Método, aparelho, mídia de armazenamento não transitório, e, programa de computador
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
BR112016027222A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
BR112017007965A2 (pt) método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit
BR112015015131A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto
CY1120515T1 (el) Παραγωγο κυκλοαλκυλικο οξεος, μεθοδος παρασκευης και φαρμακευτικη εφαρμογη αυτου
BR112015024605A2 (pt) sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo
BR112017018728A2 (pt) sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada
BR112014014124A2 (pt) Moduladores do receptor de estrogênio fluorados e usos dos mesmos
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase
BR112015030385A2 (pt) inibidores de pi3 delta e gama quinase seletivos duplos
BR112014029346A2 (pt) sistema e método implementado por computador para a montagem de um plano de tratamento médico
BR112015007843A2 (pt) método para a preparação de um polímero, polímero, artigo e método de preparação de um artigo
BR112017004056A2 (pt) composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
BR112018001438A2 (pt) expressão de fgfr e suscetibilidade a um inibidor de fgfr
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2750 DE 19-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.